Department of Medical Oncology, Netherlands Cancer Institute (NKI), Amsterdam, the Netherlands.
Department of Medical Oncology, Leiden University Medical Center (LUMC), Leiden, the Netherlands.
Cancer Discov. 2023 Nov 1;13(11):2319-2338. doi: 10.1158/2159-8290.CD-23-0352.
The introduction of immunotherapy has ushered in a new era of anticancer therapy for many cancer types including melanoma. Given the increasing development of novel compounds and combinations and the investigation in earlier disease stages, the need grows for biomarker-based treatment personalization. Stage III melanoma is one of the front-runners in the neoadjuvant immunotherapy field, facilitating quick biomarker identification by its immunogenic capacity, homogeneous patient population, and reliable efficacy readout. In this review, we discuss potential biomarkers for response prediction to neoadjuvant immunotherapy, and how the neoadjuvant melanoma platform could pave the way for biomarker identification in other tumor types.
In accordance with the increasing rate of therapy development, the need for biomarker-driven personalized treatments grows. The current landscape of neoadjuvant treatment and biomarker development in stage III melanoma can function as a poster child for these personalized treatments in other tumors, assisting in the development of new biomarker-based neoadjuvant trials. This will contribute to personalized benefit-risk predictions to identify the most beneficial treatment for each patient.
免疫疗法的引入为包括黑色素瘤在内的许多癌症类型的抗癌治疗带来了新时代。鉴于新型化合物和组合的不断发展以及早期疾病阶段的研究，基于生物标志物的治疗个体化的需求不断增长。III 期黑色素瘤是新辅助免疫治疗领域的先驱之一，其免疫原性、同质患者人群和可靠的疗效评估促进了快速生物标志物的识别。在这篇综述中，我们讨论了新辅助免疫治疗反应预测的潜在生物标志物，以及新辅助黑色素瘤平台如何为其他肿瘤类型的生物标志物识别铺平道路。
根据治疗开发速度的加快，对基于生物标志物的个体化治疗的需求也在增加。III 期黑色素瘤的新辅助治疗和生物标志物开发的现状可以作为其他肿瘤中这些个体化治疗的典范，有助于开发新的基于生物标志物的新辅助试验。这将有助于进行个性化的获益-风险预测，以确定最适合每个患者的治疗方法。
